Achillion shares should be bought ahead of data, says Piper Jaffray Piper Jaffray recommends buying Achillion's stock ahead of data from its ACH-3102 + ribavarin for HCV in April. The firm was encouraged by interim data on ACH-3102 and continues to see the company as a likely takeout candidate. It maintains an Overweight rating on the shares.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Achillion sees FY14 EPS to approach (70c), consensus (81c) The company expects that research and development expenses during 2014 will be approximately $55M-60M and that net cash used in operating activities in 2014 will be approximately $60M-65M based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs.